Robert koch redux: Malaria immunology in papua new guinea

Parasite Immunology

Volumn 32, Issue 8, 2010, Pages 623-632

  Stanisic, D I ^a   Mueller, I ^b   Betuela, I ^b   Siba, P ^b   Schofield, L ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

Author keywords

immunity; Papua New Guinea; Plasmodium

Indexed keywords

AMA 1 VACCINE; COMBINATION B VACCINE; ERYTHROCYTE MEMBRANE PROTEIN 1; FANSIDAR; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MALARIA VACCINE; MEMBRANE ANTIGEN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MONTANIDE ISA 720; TOXIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; BLOOD SMEAR; CELLULAR IMMUNITY; CLINICAL TRIAL; HOST PARASITE INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGY; INDONESIA; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MICROBIOLOGY; MICROSCOPY; MIXED INFECTION; MORBIDITY; PAPUA NEW GUINEA; PARASITE IMMUNITY; PHAGOCYTE; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK; TH1 CELL; HISTORY; MEDICAL RESEARCH; PLASMODIUM; TRENDS;

BIOMEDICAL RESEARCH; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALARIA; MALARIA VACCINES; PAPUA NEW GUINEA; PLASMODIUM;

EID: 77954641367     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2010.01238.x     Document Type: Review

References (57)

1. Mueller I, Bockarie M, Alpers M Smith T. The epidemiology of malaria in Papua New Guinea. Trends Parasitol 2003 19 (6 253 259. (Pubitemid 36638726)
2. Genton B, al-Yaman F, Beck HP, et al. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasitol 1995 89 (4 359 376.
3. Koch R. Zweiter Bericht uber die Thatigkeit der Malaria-Expedition. Dtsch Med Wochenschr 1900 26 (5 88 90. English Translation in Brit Med J Feb 10, 1900 325-327.
4. Koch R. Dritter Bericht uber die Thatigkeit der Malaria-Expedition. Dtsch Med Wochenschr 1900 26 (17 281 284. English Translation in Brit. Med. J. May 12, 1900, 1183-1186.
5. Koch R. Vieter Bericht uber die Thatigkeit der Malaria-Expedition. Dtsch Med Wochenschr 1900 26 (25 397 398. English translation in Brit. Med. J. June 30, 1900, 1597-1598.
6. Ewers W. Robert Koch, his work in New Guinea and his contribution to malariology. P N G Med J 1972 15 (2 117 124.
7. Schofield L Mueller I. Clinical immunity to malaria. Curr Mol Med 2006 6 : 205 221.
8. Clark IA Schofield L. Pathogenesis of malaria. Parasitol Today 2000 16 (10 451 454.
9. Baird JK, Jones T, Danudirgo E, et al. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg 1991 45 (1 65 76.
10. Baird JK. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 1998 92 (4 367 390.
11. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009 22 (1 13 36, Table of Contents.
12. Mehlotra RK, Lorry K, Kastens W, et al. Random distribution of mixed species infections in Papua New Guinea. Am J Trop Med Hyg 2000 62 (2 225 231.
13. Mehlotra RK, Kasehagen LJ, Baisor M, et al. Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg 2002 67 (6 555 562.
14. Mueller I, Widmer S, Michel D, et al. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar J 2009 8 : 41.
15. Smith T, Genton B, Baea K, et al. Prospective risk of morbidity in relation to malaria infection in an area of high endemicity of multiple species of Plasmodium. Am J Trop Med Hyg 2001 64 (5-6 262 267.
16. Smith T, Hii JL, Genton B, et al. Associations of peak shifts in age-prevalence for human malarias with bednet coverage. Trans R Soc Trop Med Hyg 2001 95 : 1 6.
17. Bruce MC, Donnelly CA, Packer M, et al. Age- and species-specific duration of infection in asymptomatic malaria infections in Papua New Guinea. Parasitology 2000 121 (Pt 3 247 256.
18. Bruce MC, Donnelly CA, Alpers MP, et al. Cross-species interactions between malaria parasites in humans. Science 2000 287 (5454 845 848.
19. Mueller I, Genton B, Betuela I, et al. Vaccines against malaria: perspectives from Papua New Guinea. Hum Vaccin 2010 6 (1 17 20.
20. Michon P, Cole-Tobian J, Dabod E, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 2007 76 (6 997 1008.
21. Lin E, Kiniboro B, Gray L, et al. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS ONE 2010 5 (2 e9047.
22. Salanti A, Staalsoe T, Jensen AT, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003 49 (1 179 191.
23. Jensen AT, Magistradi P, Sharp S, et al. Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J Exp Med 2004 199 (9 1179 1190.
24. D'Ombrain M, Voss T, Maier A, et al. Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon gamma. Cell Host Microbe 2007 2 : 130 138.
25. Schofield L Tachado SD. Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa. Immunol Cell Biol 1996 74 (6 555 563.
26. Tachado SD, Mazhari-Tabrizi R Schofield L. Specificity in signal transduction among glycosylphosphatidylinositols of Plasmodium falciparum, Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. Parasite Immunol 1999 21 (12 609 617.
27. Schofield L, Hewitt MC, Evans K, et al. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002 418 (6899 785 789.
28. Naik RS, Branch OH, Woods AS, et al. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J Exp Med 2000 192 (11 1563 1576.
29. Hudson Keenihan SN, Ratiwayanto S, Soebianto S, et al. Age-dependent impairment of IgG responses to glycosylphosphatidylinositol with equal exposure to Plasmodium falciparum among Javanese migrants to Papua, Indonesia. Am J Trop Med Hyg 2003 69 (1 36 41.
30. Boutlis CS, Gowda DC, Naik RS, et al. Antibodies to Plasmodium falciparum glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults. Infect Immun 2002 70 (9 5052 5057.
31. Luty AJ, Lell B, Schmidt-Ott R, et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999 179 (4 980 988.
32. Al-Yaman F, Genton B, Taraika J, et al. Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area. Parasite Immunol 1997 19 : 249 254.
33. Al-Yaman F, Genton B, Taraika J, et al. Cellular immunity to merozoite surface protein 2 (FC27 and 3D7) in Papua New Guinean children. Temporal variation and relation to clinical and parasitological status. Parasite Immunol 1997 19 : 207 214.
34. Baird JK Snow RW. Acquired immunity in a holoendemic setting of Plasmodium falciparum and P. vivax malaria. Am J Trop Med Hyg 2007 76 (6 995 996.
35. D'Ombrain M, Robinson L, Stanisic D, et al. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis 2008 47 (11 1380 1387.
36. Robinson L, D'Ombrain M, Stanisic D, et al. Cellular tumour necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malariia in children from Papua New Guinea. Infect Immun 2009 77 (7 3033 3043.
37. Xainli J, Baisor M, Kastens W, et al. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol 2002 169 : 3200 3207.
38. King C, Michon P, Shakri A, et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Scad Sci U S A 2008 105 (24 8363 8368.
39. Cohen S, McGregor IA, Carrington S, et al. Gamma-globulin and acquired immunity to human malaria. Nature 1961 192 : 733 737.
40. Genton B, Anders RF, Alpers MP, et al. The malaria vaccine development program in Papua New Guinea. Trends Parasitol 2003 19 (6 264 270.
41. Al-Yaman F, Genton B, Anders RF, et al. Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg 1994 51 (5 593 602. (Pubitemid 24378555)
42. Al-Yaman F, Genton B, Falk M, et al. Humoral response to Plasmodium falciparum ring-infected erythrocyte surface antigen in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg 1995 52 (1 66 71.
43. Al-Yaman F, Genton B, Kramer KJ, et al. Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. Trans R Soc Trop Med Hyg 1995 89 (5 555 559.
44. Beck HP, Felger I, Genton B, et al. Humoral and cell-mediated immunity to the Plasmodium falciparum ring-infected erythrocyte surface antigen in an adult population exposed to highly endemic malaria. Infect Immun 1995 63 : 596 600.
45. Beck HP, Felger I, Kabintik S, et al. Assessment of the humoral and cell-mediated immunity against the Plasmodium falciparum vaccine candidates circumsporozoite protein and SPf66 in adults living in highly endemic malarious areas of Papua New Guinea. Am J Trop Med Hyg 1994 51 (3 356 364.
46. Connelly M, King CL, Bucci K, et al. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun 1997 65 (12 5082 5087.
47. Al-Yaman F, Genton B, Kramer K, et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 1996 54 (5 443 448.
48. Al-Yaman F, Genton B, Anders R, et al. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua new Guinean children from clinical malaria. Parasite Immunol 1995 17 : 493 501.
49. Stanisic DI, Richards J, McCallum F, et al. IgG subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009 77 (3 1165 1174.
50. Malkin E, Diemert D, McArthur J, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005 73 (6 3677 3685.
51. Forsyth KP, Philip G, Smith T, et al. Diversity of antigens expressed on the surface of erythrocytes infected with mature Plasmodium falciparum parasites in Papua New Guinea. Am J Trop Med Hyg 1989 41 (3 259 265.
52. Cole-Tobian J, Michon P, Baisor M, et al. Strain-specific Duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect Immun, 2009 77 (9 4009 4017.
53. Grimberg BT, Udomsangpetch R, Xainli J, et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 2007 4 (12 e337.
54. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodum falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002 185 : 820 827.
55. Genton B, Al-Yaman F, Betuela I, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003 22 (1 30 41.
56. Fluck C, Smith T, Beck H, et al. Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun 2004 72 (11 6300 6305.
57. Hommel M, Elliott SR, Soma V, et al. Evaluating the antigenic diversity of placental binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun 2010 78 (5 1963 1978.